AstraZeneca (LON:AZN) Receives “Buy” Rating from Berenberg Bank

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reiterated by equities researchers at Berenberg Bank in a research report issued to clients and investors on Monday, Marketbeat reports. They presently have a GBX 140 ($1.74) price target on the biopharmaceutical company’s stock. Berenberg Bank’s price target suggests a potential downside of 98.75% from the stock’s current price.

Other analysts have also recently issued research reports about the company. Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a report on Thursday, November 7th. JPMorgan Chase & Co. restated an “overweight” rating and set a £140 ($174.19) price objective on shares of AstraZeneca in a research report on Friday, November 22nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of GBX 7,935.67 ($98.74).

AstraZeneca Price Performance

Shares of LON:AZN opened at £111.70 ($138.98) on Monday. The company has a 50 day moving average of £105.88 and a 200 day moving average of £115.38. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97. AstraZeneca has a 12 month low of GBX 9,461 ($117.72) and a 12 month high of £133.88 ($166.58). The stock has a market cap of £173.13 billion, a P/E ratio of 3,546.03, a P/E/G ratio of 0.86 and a beta of 0.17.

Insider Buying and Selling

In other news, insider Pascal Soriot purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, November 14th. The shares were bought at an average cost of £102.03 ($126.95) per share, for a total transaction of £2,040,600 ($2,539,007.09). Also, insider Tony Mok acquired 1,500 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was purchased at an average price of £126.80 ($157.77) per share, with a total value of £190,200 ($236,655.47). 0.04% of the stock is currently owned by insiders.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.